Literature DB >> 1364840

Anti-arrhythmic activities of opioid agonists and antagonists and their stereoisomers.

Y Sarne1, A Flitstein, E Oppenheimer.   

Abstract

1. A series of opioid agonists, antagonists and their (+)-stereoisomers were tested for antiarrhythmic activity in the rat coronary artery occlusion model. 2. Naloxone (0.01-2 mg kg-1) significantly reduced the incidence and severity of cardiac arrhythmias, in accordance with previous published studies. 3. The non-opioid stereoisomer, (+)-naloxone, was equipotent with naloxone against occlusion-induced arrhythmia. 4. Similar non-stereospecific antiarrhythmic effects were induced by another opioid antagonist, Win 44,441-3 and its stereoisomer Win 44,441-2. 5. The opioid agonists, morphine and levorphanol, protected against occlusion-induced arrhythmia as did the opioid antagonists, and the (+)-stereoisomer, dextrorphan, was equipotent to levorphanol. 6. It is concluded that the antiarrhythmic effects of opioid drugs are not mediated by opioid receptors. A direct effect on ionic currents in cardiac muscle is suggested as the mechanism of opioid antiarrhythmic activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1364840      PMCID: PMC1917956          DOI: 10.1111/j.1476-5381.1991.tb12235.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  11 in total

1.  Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone.

Authors:  I Iijima; J Minamikawa; A E Jacobson; A Brossi; K C Rice
Journal:  J Med Chem       Date:  1978-04       Impact factor: 7.446

2.  Nature of the morphine receptor present in the squid axon.

Authors:  D T Frazier; M Ohta; T Narahashi
Journal:  Proc Soc Exp Biol Med       Date:  1973-04

3.  Inhibition of ionic currents in frog node of Ranvier treated with naloxone.

Authors:  M R Carratu'; D Mitolo-Chieppa
Journal:  Br J Pharmacol       Date:  1982-09       Impact factor: 8.739

4.  Structure-activity relationships in narcotic antagonists with N-furylmethyl substituents.

Authors:  H Merz; A Langbein; K Stockhaus; G Walther; H Wick
Journal:  Adv Biochem Psychopharmacol       Date:  1973

5.  Stereospecific antiarrhythmic effect of opioid receptor antagonists in myocardial ischaemia.

Authors:  J R Parratt; R Sitsapesan
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

6.  Influence of the optical isomers (+)- and (-)-naloxone on beating frequency, contractile force and action potentials of guinea-pig isolated cardiac preparations.

Authors:  H Brasch
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

7.  Naloxone inhibits early arrhythmias resulting from acute coronary ligation.

Authors:  O Fagbemi; I Leprán; J R Parratt; L Szekeres
Journal:  Br J Pharmacol       Date:  1982-08       Impact factor: 8.739

8.  Antiarrhythmic action of naloxone: direct, non-opiate effect on the rat heart.

Authors:  Y Sarne; I Hochman; M Eshed; E Oppenheimer
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

9.  Prevention and reversal of ouabain-induced cardiotoxicity by naloxone in the guinea-pig.

Authors:  A Y Lee; T W Unang; T M Wong
Journal:  Clin Exp Pharmacol Physiol       Date:  1986-01       Impact factor: 2.557

10.  Coronary artery ligation in anesthetized rats as a method for the production of experimental dysrhythmias and for the determination of infarct size.

Authors:  C Clark; M I Foreman; K A Kane; F M McDonald; J R Parratt
Journal:  J Pharmacol Methods       Date:  1980-06
View more
  2 in total

1.  Electrophysiological and antiarrhythmic actions of the kappa agonist PD 129290, and its R,R (+)-enantiomer, PD 129289.

Authors:  M K Pugsley; D A Saint; M P Penz; M J Walker
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

2.  Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.

Authors:  M K Pugsley; W P Penz; M J Walker; T M Wong
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.